Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli ...

The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16. ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

Eli Lilly stock is down after issuing Q4 2024 guidance that missed Wall Street estimates. ... Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Eli Lilly now expects revenue to be approximately $13.5 billion for its fourth quarter and $45 billion for the full year 2024. The company had earlier forecast full-year revenue to come in between ...

The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16. ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16. ...

The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16. ...